Dehydrovomifoliol Alleviates Nonalcoholic Fatty Liver Disease <i>via</i> the E2F1/AKT/mTOR Axis: Pharmacophore Modeling and Molecular Docking Study

<div>Screening of genes regulated by E2F1 during NAFLD development. (a) A PPI network of fat cell proliferation-related genes and E2F1. (b) Screening of fat cell proliferation genes related to the core gene E2F1. (c) KEGG enrichment analysis of fat metabolism genes related to the core gene E2F1.</div>

Evidence-Based Complementary and Alternative Medicine

fig7

Figure 7

Figure 7: Dehydrovomifoliol Alleviates Nonalcoholic Fatty Liver Disease <i>via</i> the E2F1/AKT/mTOR Axis: Pharmacophore Modeling and Molecular Docking Study 

Figure 7 | Dehydrovomifoliol Alleviates Nonalcoholic Fatty Liver Disease via the E2F1/AKT/mTOR Axis: Pharmacophore Modeling and Molecular Docking Study 